Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lilly Japan Plans Excursion to Local Cities in Quest for Novel Drug Seeds
Eli Lilly Japan is planning to start its new open innovation initiative to unearth potentially promising drug seeds by taking to local cities to meet medical scientists, the company’s R&D executives told Jiho on June 4. The initiative is a…
To read the full story
Related Article
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Lilly Holds Partnering Event in Japan to Unearth Unique Seeds, R&D Chief Interested in 10-Plus Projects
September 14, 2015
- Lilly Hopes Alzheimer’s Drug Solanezumab Will Be World’s First-in-Class
June 5, 2015
- Japan Should Open Up AMED’s Achievements Globally: Lilly Execs
June 5, 2015
BUSINESS
- Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…